In [1]:
import requests
from bs4 import BeautifulSoup
import networkx
In [1]:
In [2]:
search_start = 'http://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed'
investigator = u'Jos\xe9 Carlos Fernandes Galdur\xf3z'
In [3]:
r = requests.get(search_start + '&term=%s[Author]&retmax=100000' % investigator)
In [4]:
soup = BeautifulSoup(r.text)
ids = [s.text for s in soup.find_all('id')]
In [5]:
ids
Out[5]:
[u'24974353',
u'24621460',
u'24441937',
u'24402222',
u'23997753',
u'23682773',
u'23653426',
u'23537456',
u'23321284',
u'23046856',
u'22585900',
u'22392388',
u'22390908',
u'22070228',
u'21645973',
u'21349251',
u'20557283',
u'20464178',
u'20126922',
u'19784487',
u'19722004',
u'16358094']
In [6]:
summary_start = 'http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed'
id_list = ','.join(ids)
In [7]:
r = requests.get(summary_start + '&id=%s&retmode=xml&retmax=10000' % id_list)
In [8]:
soup = BeautifulSoup(r.text)
In [13]:
print list(soup)
[u'PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2014//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_140101.dtd"', <html><body><pubmedarticleset>
<pubmedarticle>
<medlinecitation owner="NLM" status="In-Process">
<pmid version="1">24974353</pmid>
<datecreated>
<year>2014</year>
<month>08</month>
<day>01</day>
</datecreated>
<article pubmodel="Print-Electronic">
<journal>
<issn issntype="Electronic">1873-7862</issn>
<journalissue citedmedium="Internet">
<volume>24</volume>
<issue>8</issue>
<pubdate>
<year>2014</year>
<month>Aug</month>
</pubdate>
</journalissue>
<title>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</title>
<isoabbreviation>Eur Neuropsychopharmacol</isoabbreviation>
</journal>
<articletitle>Effects of biperiden on the treatment of cocaine/crack addiction: a randomised, double-blind, placebo-controlled trial.</articletitle>
<pagination>
<medlinepgn>1196-202</medlinepgn>
</pagination>
<elocationid eidtype="doi" validyn="Y">10.1016/j.euroneuro.2014.06.001</elocationid>
<elocationid eidtype="pii" validyn="Y">S0924-977X(14)00169-2</elocationid>
<abstract>
<abstracttext>Cocaine use affects approximately 13.4 million people, or 0.3% of the world's population between 15 and 64 years of age. Several authors have described drug addiction as a disease of the brain reward system. Given that the cholinergic system impacts reward mechanisms and drug self-administration, acetylcholine (ACh) might play an important role in the cocaine addiction process. We evaluated the efficacy of biperiden (a cholinergic antagonist) in reducing craving and the amount used, and in increasing compliance with treatment for cocaine/crack addiction. It was a study double-blind, randomised, placebo-controlled, 8-week trial of 111 cocaine or crack addicted male patients between 18 and 50 years old. Two groups were compared: placebo (n=55) or biperiden (n=56) combined with weekly sessions of brief group cognitive-behavioural therapy. The efficacy of treatment was evaluated according to the patients' compliance and several instruments: the Minnesota Cocaine Craving Scale, the Beck Depression and Anxiety Scales and a questionnaire assessing the amount of drug used. All of the patients attended weekly sessions for two months. We analysed the data considering the patients' intention to treat based on our last observation. Of the 56 patients in the biperiden group, 24 completed the treatment (42.8%) compared with only 11 patients in the placebo group (20%), which was a significant difference (p=0.009). Compliance with treatment was 118% higher in the biperiden group, which was also the group that presented a statistically significant reduction in the amount of cocaine/crack use (p<0.001). There was statistically significant difference between the craving score in the biperiden group. Pharmacological blockade of the cholinergic system with biperiden is a promising alternative to treat cocaine/crack addiction, helping patients to reduce the amount used and improving compliance with psychotherapy treatment.</abstracttext>
<copyrightinformation>Copyright © 2014 Elsevier B.V. and ECNP. All rights reserved.</copyrightinformation>
</abstract>
<authorlist completeyn="Y">
<author validyn="Y">
<lastname>Dieckmann</lastname>
<forename>Luiz Henrique Junqueira</forename>
<initials>LH</initials>
<affiliation>Department of Psychobiology, Universidade Federal de São Paulo, São Paulo, Brazil.</affiliation>
</author>
<author validyn="Y">
<lastname>Ramos</lastname>
<forename>Anna Carolina</forename>
<initials>AC</initials>
<affiliation>Department of Psychobiology, Universidade Federal de São Paulo, São Paulo, Brazil.</affiliation>
</author>
<author validyn="Y">
<lastname>Silva</lastname>
<forename>Eroy Aparecida</forename>
<initials>EA</initials>
<affiliation>Department of Psychobiology, Universidade Federal de São Paulo, São Paulo, Brazil.</affiliation>
</author>
<author validyn="Y">
<lastname>Justo</lastname>
<forename>Luis Pereira</forename>
<initials>LP</initials>
<affiliation>Department of Psychobiology, Universidade Federal de São Paulo, São Paulo, Brazil.</affiliation>
</author>
<author validyn="Y">
<lastname>Sabioni</lastname>
<forename>Pamela</forename>
<initials>P</initials>
<affiliation>Department of Psychobiology, Universidade Federal de São Paulo, São Paulo, Brazil.</affiliation>
</author>
<author validyn="Y">
<lastname>Frade</lastname>
<forename>Iracema Francisco</forename>
<initials>IF</initials>
<affiliation>Department of Psychobiology, Universidade Federal de São Paulo, São Paulo, Brazil.</affiliation>
</author>
<author validyn="Y">
<lastname>de Souza</lastname>
<forename>Altay Lino</forename>
<initials>AL</initials>
<affiliation>Department of Psychobiology, Universidade Federal de São Paulo, São Paulo, Brazil.</affiliation>
</author>
<author validyn="Y">
<lastname>Galduróz</lastname>
<forename>José Carlos Fernandes</forename>
<initials>JC</initials>
<affiliation>Department of Psychobiology, Universidade Federal de São Paulo, São Paulo, Brazil. Electronic address: galduroz@unifesp.br.</affiliation>
</author>
</authorlist>
<language>eng</language>
<publicationtypelist>
<publicationtype>Journal Article</publicationtype>
<publicationtype>Research Support, Non-U.S. Gov't</publicationtype>
</publicationtypelist>
<articledate datetype="Electronic">
<year>2014</year>
<month>06</month>
<day>12</day>
</articledate>
</article>
<medlinejournalinfo>
<country>Netherlands</country>
<medlineta>Eur Neuropsychopharmacol</medlineta>
<nlmuniqueid>9111390</nlmuniqueid>
<issnlinking>0924-977X</issnlinking>
</medlinejournalinfo>
<citationsubset>IM</citationsubset>
<keywordlist owner="NOTNLM">
<keyword majortopicyn="N">Biperiden</keyword>
<keyword majortopicyn="N">Cholinergic antagonist</keyword>
<keyword majortopicyn="N">Cocaine</keyword>
<keyword majortopicyn="N">Crack</keyword>
<keyword majortopicyn="N">Craving</keyword>
<keyword majortopicyn="N">Treatment</keyword>
</keywordlist>
</medlinecitation>
<pubmeddata>
<history>
<pubmedpubdate pubstatus="received">
<year>2013</year>
<month>11</month>
<day>18</day>
</pubmedpubdate>
<pubmedpubdate pubstatus="revised">
<year>2014</year>
<month>5</month>
<day>23</day>
</pubmedpubdate>
<pubmedpubdate pubstatus="accepted">
<year>2014</year>
<month>6</month>
<day>2</day>
</pubmedpubdate>
<pubmedpubdate pubstatus="aheadofprint">
<year>2014</year>
<month>6</month>
<day>12</day>
</pubmedpubdate>
<pubmedpubdate pubstatus="entrez">
<year>2014</year>
<month>6</month>
<day>30</day>
<hour>6</hour>
<minute>0</minute>
</pubmedpubdate>
<pubmedpubdate pubstatus="pubmed">
<year>2014</year>
<month>6</month>
<day>30</day>
<hour>6</hour>
<minute>0</minute>
</pubmedpubdate>
<pubmedpubdate pubstatus="medline">
<year>2014</year>
<month>6</month>
<day>30</day>
<hour>6</hour>
<minute>0</minute>
</pubmedpubdate>
</history>
<publicationstatus>ppublish</publicationstatus>
<articleidlist>
<articleid idtype="pubmed">24974353</articleid>
<articleid idtype="pii">S0924-977X(14)00169-2</articleid>
<articleid idtype="doi">10.1016/j.euroneuro.2014.06.001</articleid>
</articleidlist>
</pubmeddata>
</pubmedarticle>
<pubmedarticle>
<medlinecitation owner="NLM" status="Publisher">
<pmid version="1">24621460</pmid>
<datecreated>
<year>2014</year>
<month>3</month>
<day>13</day>
</datecreated>
<article pubmodel="Print-Electronic">
<journal>
<issn issntype="Electronic">1557-1246</issn>
<journalissue citedmedium="Internet">
<pubdate>
<year>2014</year>
<month>Mar</month>
<day>12</day>
</pubdate>
</journalissue>
<title>Journal of attention disorders</title>
<isoabbreviation>J Atten Disord</isoabbreviation>
</journal>
<articletitle>Possible Cognitive Benefits of Acute Physical Exercise in Children With ADHD: A Systematic Review.</articletitle>
<pagination>
<medlinepgn></medlinepgn>
</pagination>
<abstract>
<abstracttext nlmcategory="UNLABELLED">Objective: Studies have suggested that even a single session of physical exercise enhances executive functions. ADHD is among the most common developmental disorders in childhood, but little is known about alternative treatments for this disorder. Therefore, we performed a systematic review of the literature to analyze articles that evaluated the executive functions of children with ADHD after an acute exercise session. Method: We reviewed articles indexed in the PubMed, American Psychiatric Association (APA) psychNET, Scopus, and Web of Knowledge databases between 1980 and 2013. Results: Of 231 articles selected, only three met the inclusion criteria. Conclusion: Based on these 3 articles, we concluded that 30 min of physical exercise reportedly improved the executive functions of children with ADHD. Due to the small number of articles selected, further studies are needed to confirm these benefits.</abstracttext>
</abstract>
<authorlist>
<author>
<lastname>Grassmann</lastname>
<forename>Viviane</forename>
<initials>V</initials>
<affiliation>1Universidade Federal de São Paulo, Brazil.</affiliation>
</author>
<author>
<lastname>Alves</lastname>
<forename>Marcus Vinicius</forename>
<initials>MV</initials>
</author>
<author>
<lastname>Santos-Galduróz</lastname>
<forename>Ruth Ferreira</forename>
<initials>RF</initials>
</author>
<author>
<lastname>Galduróz</lastname>
<forename>José Carlos Fernandes</forename>
<initials>JC</initials>
</author>
</authorlist>
<language>ENG</language>
<publicationtypelist>
<publicationtype>JOURNAL ARTICLE</publicationtype>
</publicationtypelist>
<articledate datetype="Electronic">
<year>2014</year>
<month>3</month>
<day>12</day>
</articledate>
</article>
<medlinejournalinfo>
<medlineta>J Atten Disord</medlineta>
<nlmuniqueid>9615686</nlmuniqueid>
<issnlinking>1087-0547</issnlinking>
</medlinejournalinfo>
<keywordlist owner="NOTNLM">
<keyword majortopicyn="N">ADHD</keyword>
<keyword majortopicyn="N">acute exercise</keyword>
<keyword majortopicyn="N">children</keyword>
<keyword majortopicyn="N">cognitive functions</keyword>
<keyword majortopicyn="N">physical exercise</keyword>
</keywordlist>
</medlinecitation>
<pubmeddata>
<history>
<pubmedpubdate pubstatus="entrez">
<year>2014</year>
<month>3</month>
<day>14</day>
<hour>6</hour>
<minute>0</minute>
</pubmedpubdate>
<pubmedpubdate pubstatus="pubmed">
<year>2014</year>
<month>3</month>
<day>14</day>
<hour>6</hour>
<minute>0</minute>
</pubmedpubdate>
<pubmedpubdate pubstatus="medline">
<year>2014</year>
<month>3</month>
<day>14</day>
<hour>6</hour>
<minute>0</minute>
</pubmedpubdate>
</history>
<publicationstatus>aheadofprint</publicationstatus>
<articleidlist>
<articleid idtype="pii">1087054714526041</articleid>
<articleid idtype="doi">10.1177/1087054714526041</articleid>
<articleid idtype="pubmed">24621460</articleid>
</articleidlist>
</pubmeddata>
</pubmedarticle>
<pubmedarticle>
<medlinecitation owner="NLM" status="MEDLINE">
<pmid version="1">24441937</pmid>
<datecreated>
<year>2014</year>
<month>01</month>
<day>30</day>
</datecreated>
<datecompleted>
<year>2014</year>
<month>10</month>
<day>10</day>
</datecompleted>
<article pubmodel="Print-Electronic">
<journal>
<issn issntype="Electronic">1432-2072</issn>
<journalissue citedmedium="Internet">
<volume>231</volume>
<issue>4</issue>
<pubdate>
<year>2014</year>
<month>Feb</month>
</pubdate>
</journalissue>
<title>Psychopharmacology</title>
<isoabbreviation>Psychopharmacology (Berl.)</isoabbreviation>
</journal>
<articletitle>Tamoxifen use for the management of mania: a review of current preclinical evidence.</articletitle>
<pagination>
<medlinepgn>639-49</medlinepgn>
</pagination>
<elocationid eidtype="doi" validyn="Y">10.1007/s00213-013-3397-x</elocationid>
<abstract>
<abstracttext label="RATIONALE" nlmcategory="BACKGROUND">Preliminary data on the efficacy of tamoxifen in reducing manic symptoms of bipolar disorder (BD) suggest that this agent may be a potential treatment for the management of this psychiatric disorder. However, the antimanic properties of tamoxifen have not been fully elucidated, hampering the development and/or use of mood-stabilising drugs that may share its same therapeutic mechanisms of action. Notably, we may gain a greater understanding of the neurobiological and therapeutic properties of tamoxifen by using suitable animal models of mania.</abstracttext>
<abstracttext label="OBJECTIVES" nlmcategory="OBJECTIVE">Here, we review the preclinical studies that have evaluated the effects of tamoxifen to provide an overview of the current progress in our understanding of its antimanic actions, highlighting the critical role of protein kinase C (PKC) as a therapeutic target for the treatment of BD.</abstracttext>
<abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">To date, this field has struggled to make significant progress, and the organisation of an explicit battery of tests is a valuable tool for assessing a number of prominent facets of BD, which may provide a greater understanding of the entire scope of this disease.</abstracttext>
</abstract>
<authorlist completeyn="Y">
<author validyn="Y">
<lastname>Armani</lastname>
<forename>Fernanda</forename>
<initials>F</initials>
<affiliation>Departamento de Psicobiologia, Universidade Federal de São Paulo, São Paulo, SP, Brazil.</affiliation>
</author>
<author validyn="Y">
<lastname>Andersen</lastname>
<forename>Monica Levy</forename>
<initials>ML</initials>
</author>
<author validyn="Y">
<lastname>Galduróz</lastname>
<forename>José Carlos Fernandes</forename>
<initials>JC</initials>
</author>
</authorlist>
<language>eng</language>
<publicationtypelist>
<publicationtype>Journal Article</publicationtype>
<publicationtype>Review</publicationtype>
</publicationtypelist>
<articledate datetype="Electronic">
<year>2014</year>
<month>01</month>
<day>18</day>
</articledate>
</article>
<medlinejournalinfo>
<country>Germany</country>
<medlineta>Psychopharmacology (Berl)</medlineta>
<nlmuniqueid>7608025</nlmuniqueid>
<issnlinking>0033-3158</issnlinking>
</medlinejournalinfo>
<chemicallist>
<chemical>
<registrynumber>0</registrynumber>
<nameofsubstance>Antimanic Agents</nameofsubstance>
</chemical>
<chemical>
<registrynumber>094ZI81Y45</registrynumber>
<nameofsubstance>Tamoxifen</nameofsubstance>
</chemical>
<chemical>
<registrynumber>EC 2.7.11.13</registrynumber>
<nameofsubstance>Protein Kinase C</nameofsubstance>
</chemical>
</chemicallist>
<citationsubset>IM</citationsubset>
<meshheadinglist>
<meshheading>
<descriptorname majortopicyn="N">Animals</descriptorname>
</meshheading>
<meshheading>
<descriptorname majortopicyn="N">Antimanic Agents</descriptorname>
<qualifiername majortopicyn="N">pharmacology</qualifiername>
<qualifiername majortopicyn="Y">therapeutic use</qualifiername>
</meshheading>
<meshheading>
<descriptorname majortopicyn="N">Bipolar Disorder</descriptorname>
<qualifiername majortopicyn="Y">drug therapy</qualifiername>
<qualifiername majortopicyn="N">metabolism</qualifiername>
</meshheading>
<meshheading>
<descriptorname majortopicyn="N">Disease Models, Animal</descriptorname>
</meshheading>
<meshheading>
<descriptorname majortopicyn="N">Humans</descriptorname>
</meshheading>
<meshheading>
<descriptorname majortopicyn="N">Protein Kinase C</descriptorname>
<qualifiername majortopicyn="N">antagonists & inhibitors</qualifiername>
<qualifiername majortopicyn="N">metabolism</qualifiername>
</meshheading>
<meshheading>
<descriptorname majortopicyn="N">Tamoxifen</descriptorname>
<qualifiername majortopicyn="N">pharmacology</qualifiername>
<qualifiername majortopicyn="Y">therapeutic use</qualifiername>
</meshheading>
</meshheadinglist>
</medlinecitation>
<pubmeddata>
<history>
<pubmedpubdate pubstatus="received">
<year>2013</year>
<month>7</month>
<day>3</day>
</pubmedpubdate>
<pubmedpubdate pubstatus="accepted">
<year>2013</year>
<month>12</month>
<day>4</day>
</pubmedpubdate>
<pubmedpubdate pubstatus="aheadofprint">
<year>2014</year>
<month>1</month>
<day>18</day>
</pubmedpubdate>
<pubmedpubdate pubstatus="entrez">
<year>2014</year>
<month>1</month>
<day>21</day>
<hour>6</hour>
<minute>0</minute>
</pubmedpubdate>
<pubmedpubdate pubstatus="pubmed">
<year>2014</year>
<month>1</month>
<day>21</day>
<hour>6</hour>
<minute>0</minute>
</pubmedpubdate>
<pubmedpubdate pubstatus="medline">
<year>2014</year>
<month>10</month>
<day>11</day>
<hour>6</hour>
<minute>0</minute>
</pubmedpubdate>
</history>
<publicationstatus>ppublish</publicationstatus>
<articleidlist>
<articleid idtype="doi">10.1007/s00213-013-3397-x</articleid>
<articleid idtype="pubmed">24441937</articleid>
</articleidlist>
</pubmeddata>
</pubmedarticle>
<pubmedarticle>
<medlinecitation owner="NLM" status="MEDLINE">
<pmid version="1">24402222</pmid>
<datecreated>
<year>2014</year>
<month>01</month>
<day>09</day>
</datecreated>
<datecompleted>
<year>2014</year>
<month>07</month>
<day>11</day>
</datecompleted>
<article pubmodel="Print-Electronic">
<journal>
<issn issntype="Electronic">1809-452X</issn>
<journalissue citedmedium="Internet">
<volume>35</volume>
<issue>4</issue>
<pubdate>
<medlinedate>2013 Oct-Dec</medlinedate>
</pubdate>
</journalissue>
<title>Revista brasileira de psiquiatria (São Paulo, Brazil : 1999)</title>
<isoabbreviation>Rev Bras Psiquiatr</isoabbreviation>
</journal>
<articletitle>Varenicline: the risks of over-the-counter sales in Brazil.</articletitle>
<pagination>
<medlinepgn>442-3</medlinepgn>
</pagination>
<elocationid eidtype="doi" validyn="Y">10.1590/1516-4446-2013-1107</elocationid>
<elocationid eidtype="pii" validyn="Y">S1516-44462013000400442</elocationid>
<authorlist completeyn="Y">
<author validyn="Y">
<lastname>Zaparoli</lastname>
<forename>Juçara Xavier</forename>
<initials>JX</initials>
<affiliation>Universidade Federal de São Paulo (UNIFESP), Department of Psychobiology, São PauloSP, Brazil.</affiliation>
</author>
<author validyn="Y">
<lastname>Galduróz</lastname>
<forename>José Carlos Fernandes</forename>
<initials>JC</initials>
<affiliation>Universidade Federal de São Paulo (UNIFESP), Department of Psychobiology, São PauloSP, Brazil.</affiliation>
</author>
</authorlist>
<language>eng</language>
<publicationtypelist>
<publicationtype>Letter</publicationtype>
<publicationtype>Research Support, Non-U.S. Gov't</publicationtype>
</publicationtypelist>
<articledate datetype="Electronic">
<year>2013</year>
<month>12</month>
<day>23</day>
</articledate>
</article>
<medlinejournalinfo>
<country>Brazil</country>
<medlineta>Rev Bras Psiquiatr</medlineta>
<nlmuniqueid>100895975</nlmuniqueid>
<issnlinking>1516-4446</issnlinking>
</medlinejournalinfo>
<chemicallist>
<chemical>
<registrynumber>0</registrynumber>
<nameofsubstance>Benzazepines</nameofsubstance>
</chemical>
<chemical>
<registrynumber>0</registrynumber>
<nameofsubstance>Nicotinic Agonists</nameofsubstance>
</chemical>
<chemical>
<registrynumber>0</registrynumber>
<nameofsubstance>Nonprescription Drugs</nameofsubstance>
</chemical>
<chemical>
<registrynumber>0</registrynumber>
<nameofsubstance>Quinoxalines</nameofsubstance>
</chemical>
<chemical>
<registrynumber>W6HS99O8ZO</registrynumber>
<nameofsubstance>varenicline</nameofsubstance>
</chemical>
</chemicallist>
<citationsubset>IM</citationsubset>
<meshheadinglist>
<meshheading>
<descriptorname majortopicyn="N">Benzazepines</descriptorname>
<qualifiername majortopicyn="Y">adverse effects</qualifiername>
</meshheading>
<meshheading>
<descriptorname majortopicyn="N" type="Geographic">Brazil</descriptorname>
</meshheading>
<meshheading>
<descriptorname majortopicyn="N">Humans</descriptorname>
</meshheading>
<meshheading>
<descriptorname majortopicyn="N">Nicotinic Agonists</descriptorname>
<qualifiername majortopicyn="Y">adverse effects</qualifiername>
</meshheading>
<meshheading>
<descriptorname majortopicyn="N">Nonprescription Drugs</descriptorname>
</meshheading>
<meshheading>
<descriptorname majortopicyn="N">Quinoxalines</descriptorname>
<qualifiername majortopicyn="Y">adverse effects</qualifiername>
</meshheading>
<meshheading>
<descriptorname majortopicyn="N">Smoking</descriptorname>
<qualifiername majortopicyn="Y">drug therapy</qualifiername>
</meshheading>
<meshheading>
<descriptorname majortopicyn="Y">Smoking Cessation</descriptorname>
</meshheading>
</meshheadinglist>
</medlinecitation>
<pubmeddata>
<history>
<pubmedpubdate pubstatus="received">
<year>2013</year>
<month>2</month>
<day>18</day>
</pubmedpubdate>
<pubmedpubdate pubstatus="accepted">
<year>2013</year>
<month>4</month>
<day>1</day>
</pubmedpubdate>
<pubmedpubdate pubstatus="aheadofprint">
<year>2013</year>
<month>12</month>
<day>23</day>
</pubmedpubdate>
<pubmedpubdate pubstatus="entrez">
<year>2014</year>
<month>1</month>
<day>10</day>
<hour>6</hour>
<minute>0</minute>
</pubmedpubdate>
<pubmedpubdate pubstatus="pubmed">
<year>2014</year>
<month>1</month>
<day>10</day>
<hour>6</hour>
<minute>0</minute>
</pubmedpubdate>
<pubmedpubdate pubstatus="medline">
<year>2014</year>
<month>7</month>
<day>12</day>
<hour>6</hour>
<minute>0</minute>
</pubmedpubdate>
</history>
<publicationstatus>ppublish</publicationstatus>
<articleidlist>
<articleid idtype="pii">S1516-44462013000400442</articleid>
<articleid idtype="doi">10.1590/1516-4446-2013-1107</articleid>
<articleid idtype="pubmed">24402222</articleid>
</articleidlist>
</pubmeddata>
</pubmedarticle>
<pubmedarticle>
<medlinecitation owner="NLM" status="PubMed-not-MEDLINE">
<pmid version="1">23997753</pmid>
<datecreated>
<year>2013</year>
<month>09</month>
<day>02</day>
</datecreated>
<datecompleted>
<year>2013</year>
<month>09</month>
<day>02</day>
</datecompleted>
<daterevised>
<year>2013</year>
<month>09</month>
<day>04</day>
</daterevised>
<article pubmodel="Print">
<journal>
<issn issntype="Print">1570-159X</issn>
<journalissue citedmedium="Print">
<volume>11</volume>
<issue>2</issue>
<pubdate>
<year>2013</year>
<month>Mar</month>
</pubdate>
</journalissue>
<title>Current neuropharmacology</title>
<isoabbreviation>Curr Neuropharmacol</isoabbreviation>
</journal>
<articletitle>Effects of low doses of polyunsaturated Fatty acids on the attention deficit/hyperactivity disorder of children: a systematic review.</articletitle>
<pagination>
<medlinepgn>186-96</medlinepgn>
</pagination>
<elocationid eidtype="doi" validyn="Y">10.2174/1570159X11311020005</elocationid>
<abstract>
<abstracttext label="UNLABELLED">Since attention deficit/hyperactivity disorder (ADHD) presents high prevalence among children, science has been researching alternative forms of treatment that do not involve medication.</abstracttext>
<abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">To evaluate the effects of polyunsaturated fatty acids (PUFAs) on attention deficit/hyperactivity disorder.</abstracttext>
<abstracttext label="METHODS" nlmcategory="METHODS">We reviewed the articles published between 1980 and 2012 indexed in the databases PubMed, APA psychNET, Scopus and Web of Knowledge.</abstracttext>
<abstracttext label="RESULTS" nlmcategory="RESULTS">Initially 231 articles were selected, out of which 12 met the inclusion criteria. The articles selected reported a modest cognitive and behavioral improvement of the patients after treatment with low doses of PUFAs. Those results might be associated with the evaluation methodology, the doses of PUFAs administered or the duration of treatment.</abstracttext>
</abstract>
<authorlist completeyn="Y">
<author validyn="Y">
<lastname>Grassmann</lastname>
<forename>Viviane</forename>
<initials>V</initials>
<affiliation>Department of Psychobiology (Departamento de Psicobiologia) - Universidade Federal de São Paulo - Brazil.</affiliation>
</author>
<author validyn="Y">
<lastname>Santos-Galduróz</lastname>
<forename>Ruth Ferreira</forename>
<initials>RF</initials>
</author>
<author validyn=""> <affiliation>Department of Psychobiology (Departamento de Psicobiologia) - Universidade Federal de São Paulo - Brazil.</affiliation>
<author validyn="Y">
<lastname>Santos-Galduróz</lastname>
<forename>Ruth Ferreira</forename>
<initials>RF</initials>
</author>
<author validyn=""> <journalissue citedmedium="Internet">
<volume>24</volume>
<issue>8</issue>
<pubdate>
<year>2014</year>
<month>Aug</month>
</pubdate>
</journalissue>
<title>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</title>
<isoabbreviation>Eur Neuropsychopharmacol</isoabbreviation>
<articletitle>Effects of biperiden on the treatment of cocaine/crack addiction: a randomised, double-blind, placebo-controlled trial.</articletitle>
<pagination>
<medlinepgn>1196-202</medlinepgn>
</pagination>
<elocationid eidtype="doi" validyn="Y">10.1016/j.euroneuro.2014.06.001</elocationid>
<elocationid eidtype="pii" validyn="Y">S0924-977X(14)00169-2</elocationid>
<abstract>
<abstracttext>Cocaine use affects approximately 13.4 million people, or 0.3% of the world's population between 15 and 64 years of age. Several authors have described drug addiction as a disease of the brain reward system. Given that the cholinergic system impacts reward mechanisms and drug self-administration, acetylcholine (ACh) might play an important role in the cocaine addiction process. We evaluated the efficacy of biperiden (a cholinergic antagonist) in reducing craving and the amount used, and in increasing compliance with treatment for cocaine/crack addiction. It was a study double-blind, randomised, placebo-controlled, 8-week trial of 111 cocaine or crack addicted male patients between 18 and 50 years old. Two groups were compared: placebo (n=55) or biperiden (n=56) combined with weekly sessions of brief group cognitive-behavioural therapy. The efficacy of treatment was evaluated according to the patients' compliance and several instruments: the Minnesota Cocaine Craving Scale, the Beck Depression and Anxiety Scales and a questionnaire assessing the amount of drug used. All of the patients attended weekly sessions for two months. We analysed the data considering the patients' intention to treat based on our last observation. Of the 56 patients in the biperiden group, 24 completed the treatment (42.8%) compared with only 11 patients in the placebo group (20%), which was a significant difference (p=0.009). Compliance with treatment was 118% higher in the biperiden group, which was also the group that presented a statistically significant reduction in the amount of cocaine/crack use (p<0.001). There was statistically significant difference between the craving score in the biperiden group. Pharmacological blockade of the cholinergic system with biperiden is a promising alternative to treat cocaine/crack addiction, helping patients to reduce the amount used and improving compliance with psychotherapy treatment.</abstracttext>
<copyrightinformation>Copyright © 2014 Elsevier B.V. and ECNP. All rights reserved.</copyrightinformation>
</abstract>
<authorlist completeyn="Y">
<author validyn="Y">
<lastname>Dieckmann</lastname>
<forename>Luiz Henrique Junqueira</forename>
<initials>LH</initials>
<affiliation>Department of Psychobiology, Universidade Federal de São Paulo, São Paulo, Brazil.</affiliation>
</author>
<author validyn="Y">
<lastname>Ramos</lastname>
<forename>Anna Carolina</forename>
<initials>AC</initials>
<affiliation>Department of Psychobiology, Universidade Federal de São Paulo, São Paulo, Brazil.</affiliation>
</author>
<author validyn="Y">
<lastname>Silva</lastname>
<forename>Eroy Aparecida</forename>
<initials>EA</initials>
<affiliation>Department of Psychobiology, Universidade Federal de São Paulo, São Paulo, Brazil.</affiliation>
</author>
<author validyn="Y">
<lastname>Justo</lastname>
<forename>Luis Pereira</forename>
<initials>LP</initials>
<affiliation>Department of Psychobiology, Universidade Federal de São Paulo, São Paulo, Brazil.</affiliation>
</author>
<author validyn="Y">
<lastname>Sabioni</lastname>
<forename>Pamela</forename>
<initials>P</initials>
<affiliation>Department of Psychobiology, Universidade Federal de São Paulo, São Paulo, Brazil.</affiliation>
</author>
<author validyn="Y">
<lastname>Frade</lastname>
<forename>Iracema Francisco</forename>
<initials>IF</initials>
<affiliation>Department of Psychobiology, Universidade Federal de São Paulo, São Paulo, Brazil.</affiliation>
</author>
<author validyn="Y">
<lastname>de Souza</lastname>
<forename>Altay Lino</forename>
<initials>AL</initials>
<affiliation>Department of Psychobiology, Universidade Federal de São Paulo, São Paulo, Brazil.</affiliation>
</author>
<author validyn="Y">
<lastname>Galduróz</lastname>
<forename>José Carlos Fernandes</forename>
<initials>JC</initials>
<affiliation>Department of Psychobiology, Universidade Federal de São Paulo, São Paulo, Brazil. Electronic address: galduroz@unifesp.br.</affiliation>
</author>
</authorlist>
<language>eng</language>
<publicationtypelist>
<publicationtype>Journal Article</publicationtype>
<publicationtype>Research Support, Non-U.S. Gov't</publicationtype>
</publicationtypelist>
<articledate datetype="Electronic">
<year>2014</year>
<month>06</month>
<day>12</day>
</articledate>
</author></author></authorlist></article>
<medlinejournalinfo>
<country>Netherlands</country>
<medlineta>Eur Neuropsychopharmacol</medlineta>
<nlmuniqueid>9111390</nlmuniqueid>
<issnlinking>0924-977X</issnlinking>
</medlinejournalinfo>
<citationsubset>IM</citationsubset>
<keywordlist owner="NOTNLM">
<keyword majortopicyn="N">Biperiden</keyword>
<keyword majortopicyn="N">Cholinergic antagonist</keyword>
<keyword majortopicyn="N">Cocaine</keyword>
<keyword majortopicyn="N">Crack</keyword>
<keyword majortopicyn="N">Craving</keyword>
<keyword majortopicyn="N">Treatment</keyword>
</keywordlist>
</medlinecitation>
<pubmeddata>
<history>
<pubmedpubdate pubstatus="received">
<year>2013</year>
<month>11</month>
<day>18</day>
</pubmedpubdate>
<pubmedpubdate pubstatus="revised">
<year>2014</year>
<month>5</month>
<day>23</day>
</pubmedpubdate>
<pubmedpubdate pubstatus="accepted">
<year>2014</year>
<month>6</month>
<day>2</day>
</pubmedpubdate>
<pubmedpubdate pubstatus="aheadofprint">
<year>2014</year>
<month>6</month>
<day>12</day>
</pubmedpubdate>
<pubmedpubdate pubstatus="entrez">
<year>2014</year>
<month>6</month>
<day>30</day>
<hour>6</hour>
<minute>0</minute>
</pubmedpubdate>
<pubmedpubdate pubstatus="pubmed">
<year>2014</year>
<month>6</month>
<day>30</day>
<hour>6</hour>
<minute>0</minute>
</pubmedpubdate>
<pubmedpubdate pubstatus="medline">
<year>2014</year>
<month>6</month>
<day>30</day>
<hour>6</hour>
<minute>0</minute>
</pubmedpubdate>
</history>
<publicationstatus>ppublish</publicationstatus>
<articleidlist>
<articleid idtype="pubmed">24974353</articleid>
<articleid idtype="pii">S0924-977X(14)00169-2</articleid>
<articleid idtype="doi">10.1016/j.euroneuro.2014.06.001</articleid>
</articleidlist>
</pubmeddata>
</pubmedarticle>
<pubmedarticle>
<medlinecitation owner="NLM" status="Publisher">
<pmid version="1">24621460</pmid>
<datecreated>
<year>2014</year>
<month>3</month>
<day>13</day>
</datecreated>
<article pubmodel="Print-Electronic">
<journal>
<issn issntype="Electronic">1557-1246</issn>
<journalissue citedmedium="Internet">
<pubdate>
<year>2014</year>
<month>Mar</month>
<day>12</day>
</pubdate>
</journalissue>
<title>Journal of attention disorders</title>
<isoabbreviation>J Atten Disord</isoabbreviation>
</journal>
<articletitle>Possible Cognitive Benefits of Acute Physical Exercise in Children With ADHD: A Systematic Review.</articletitle>
<pagination>
<medlinepgn></medlinepgn>
</pagination>
<abstract>
<abstracttext nlmcategory="UNLABELLED">Objective: Studies have suggested that even a single session of physical exercise enhances executive functions. ADHD is among the most common developmental disorders in childhood, but little is known about alternative treatments for this disorder. Therefore, we performed a systematic review of the literature to analyze articles that evaluated the executive functions of children with ADHD after an acute exercise session. Method: We reviewed articles indexed in the PubMed, American Psychiatric Association (APA) psychNET, Scopus, and Web of Knowledge databases between 1980 and 2013. Results: Of 231 articles selected, only three met the inclusion criteria. Conclusion: Based on these 3 articles, we concluded that 30 min of physical exercise reportedly improved the executive functions of children with ADHD. Due to the small number of articles selected, further studies are needed to confirm these benefits.</abstracttext>
</abstract>
<authorlist>
<author>
<lastname>Grassmann</lastname>
<forename>Viviane</forename>
<initials>V</initials>
<affiliation>1Universidade Federal de São Paulo, Brazil.</affiliation>
</author>
<author>
<lastname>Alves</lastname>
<forename>Marcus Vinicius</forename>
<initials>MV</initials>
</author>
<author>
<lastname>Santos-Galduróz</lastname>
<forename>Ruth Ferreira</forename>
<initials>RF</initials>
</author>
<author>
<lastname>Galduróz</lastname>
<forename>José Carlos Fernandes</forename>
<initials>JC</initials>
</author>
</authorlist>
<language>ENG</language>
<publicationtypelist>
<publicationtype>JOURNAL ARTICLE</publicationtype>
</publicationtypelist>
<articledate datetype="Electronic">
<year>2014</year>
<month>3</month>
<day>12</day>
</articledate>
</article>
<medlinejournalinfo>
<medlineta>J Atten Disord</medlineta>
<nlmuniqueid>9615686</nlmuniqueid>
<issnlinking>1087-0547</issnlinking>
</medlinejournalinfo>
<keywordlist owner="NOTNLM">
<keyword majortopicyn="N">ADHD</keyword>
<keyword majortopicyn="N">acute exercise</keyword>
<keyword majortopicyn="N">children</keyword>
<keyword majortopicyn="N">cognitive functions</keyword>
<keyword majortopicyn="N">physical exercise</keyword>
</keywordlist>
</medlinecitation>
<pubmeddata>
<history>
<pubmedpubdate pubstatus="entrez">
<year>2014</year>
<month>3</month>
<day>14</day>
<hour>6</hour>
<minute>0</minute>
</pubmedpubdate>
<pubmedpubdate pubstatus="pubmed">
<year>2014</year>
<month>3</month>
<day>14</day>
<hour>6</hour>
<minute>0</minute>
</pubmedpubdate>
<pubmedpubdate pubstatus="medline">
<year>2014</year>
<month>3</month>
<day>14</day>
<hour>6</hour>
<minute>0</minute>
</pubmedpubdate>
</history>
<publicationstatus>aheadofprint</publicationstatus>
<articleidlist>
<articleid idtype="pii">1087054714526041</articleid>
<articleid idtype="doi">10.1177/1087054714526041</articleid>
<articleid idtype="pubmed">24621460</articleid>
</articleidlist>
</pubmeddata>
</pubmedarticle>
<pubmedarticle>
<medlinecitation owner="NLM" status="MEDLINE">
<pmid version="1">24441937</pmid>
<datecreated>
<year>2014</year>
<month>01</month>
<day>30</day>
</datecreated>
<datecompleted>
<year>2014</year>
<month>10</month>
<day>10</day>
</datecompleted>
<article pubmodel="Print-Electronic">
<journal>
<issn issntype="Electronic">1432-2072</issn>
<journalissue citedmedium="Internet">
<volume>231</volume>
<issue>4</issue>
<pubdate>
<year>2014</year>
<month>Feb</month>
</pubdate>
</journalissue>
<title>Psychopharmacology</title>
<isoabbreviation>Psychopharmacology (Berl.)</isoabbreviation>
</journal>
<articletitle>Tamoxifen use for the management of mania: a review of current preclinical evidence.</articletitle>
<pagination>
<medlinepgn>639-49</medlinepgn>
</pagination>
<elocationid eidtype="doi" validyn="Y">10.1007/s00213-013-3397-x</elocationid>
<abstract>
<abstracttext label="RATIONALE" nlmcategory="BACKGROUND">Preliminary data on the efficacy of tamoxifen in reducing manic symptoms of bipolar disorder (BD) suggest that this agent may be a potential treatment for the management of this psychiatric disorder. However, the antimanic properties of tamoxifen have not been fully elucidated, hampering the development and/or use of mood-stabilising drugs that may share its same therapeutic mechanisms of action. Notably, we may gain a greater understanding of the neurobiological and therapeutic properties of tamoxifen by using suitable animal models of mania.</abstracttext>
<abstracttext label="OBJECTIVES" nlmcategory="OBJECTIVE">Here, we review the preclinical studies that have evaluated the effects of tamoxifen to provide an overview of the current progress in our understanding of its antimanic actions, highlighting the critical role of protein kinase C (PKC) as a therapeutic target for the treatment of BD.</abstracttext>
<abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">To date, this field has struggled to make significant progress, and the organisation of an explicit battery of tests is a valuable tool for assessing a number of prominent facets of BD, which may provide a greater understanding of the entire scope of this disease.</abstracttext>
</abstract>
<authorlist completeyn="Y">
<author validyn="Y">
<lastname>Armani</lastname>
<forename>Fernanda</forename>
<initials>F</initials>
<affiliation>Departamento de Psicobiologia, Universidade Federal de São Paulo, São Paulo, SP, Brazil.</affiliation>
</author>
<author validyn="Y">
<lastname>Andersen</lastname>
<forename>Monica Levy</forename>
<initials>ML</initials>
</author>
<author validyn="Y">
<lastname>Galduróz</lastname>
<forename>José Carlos Fernandes</forename>
<initials>JC</initials>
</author>
</authorlist>
<language>eng</language>
<publicationtypelist>
<publicationtype>Journal Article</publicationtype>
<publicationtype>Review</publicationtype>
</publicationtypelist>
<articledate datetype="Electronic">
<year>2014</year>
<month>01</month>
<day>18</day>
</articledate>
</article>
<medlinejournalinfo>
<country>Germany</country>
<medlineta>Psychopharmacology (Berl)</medlineta>
<nlmuniqueid>7608025</nlmuniqueid>
<issnlinking>0033-3158</issnlinking>
</medlinejournalinfo>
<chemicallist>
<chemical>
<registrynumber>0</registrynumber>
<nameofsubstance>Antimanic Agents</nameofsubstance>
</chemical>
<chemical>
<registrynumber>094ZI81Y45</registrynumber>
<nameofsubstance>Tamoxifen</nameofsubstance>
</chemical>
<chemical>
<registrynumber>EC 2.7.11.13</registrynumber>
<nameofsubstance>Protein Kinase C</nameofsubstance>
</chemical>
</chemicallist>
<citationsubset>IM</citationsubset>
<meshheadinglist>
<meshheading>
<descriptorname majortopicyn="N">Animals</descriptorname>
</meshheading>
<meshheading>
<descriptorname majortopicyn="N">Antimanic Agents</descriptorname>
<qualifiername majortopicyn="N">pharmacology</qualifiername>
<qualifiername majortopicyn="Y">therapeutic use</qualifiername>
</meshheading>
<meshheading>
<descriptorname majortopicyn="N">Bipolar Disorder</descriptorname>
<qualifiername majortopicyn="Y">drug therapy</qualifiername>
<qualifiername majortopicyn="N">metabolism</qualifiername>
</meshheading>
<meshheading>
<descriptorname majortopicyn="N">Disease Models, Animal</descriptorname>
</meshheading>
<meshheading>
<descriptorname majortopicyn="N">Humans</descriptorname>
</meshheading>
<meshheading>
<descriptorname majortopicyn="N">Protein Kinase C</descriptorname>
<qualifiername majortopicyn="N">antagonists & inhibitors</qualifiername>
<qualifiername majortopicyn="N">metabolism</qualifiername>
</meshheading>
<meshheading>
<descriptorname majortopicyn="N">Tamoxifen</descriptorname>
<qualifiername majortopicyn="N">pharmacology</qualifiername>
<qualifiername majortopicyn="Y">therapeutic use</qualifiername>
</meshheading>
</meshheadinglist>
</medlinecitation>
<pubmeddata>
<history>
<pubmedpubdate pubstatus="received">
<year>2013</year>
<month>7</month>
<day>3</day>
</pubmedpubdate>
<pubmedpubdate pubstatus="accepted">
<year>2013</year>
<month>12</month>
<day>4</day>
</pubmedpubdate>
<pubmedpubdate pubstatus="aheadofprint">
<year>2014</year>
<month>1</month>
<day>18</day>
</pubmedpubdate>
<pubmedpubdate pubstatus="entrez">
<year>2014</year>
<month>1</month>
<day>21</day>
<hour>6</hour>
<minute>0</minute>
</pubmedpubdate>
<pubmedpubdate pubstatus="pubmed">
<year>2014</year>
<month>1</month>
<day>21</day>
<hour>6</hour>
<minute>0</minute>
</pubmedpubdate>
<pubmedpubdate pubstatus="medline">
<year>2014</year>
<month>10</month>
<day>11</day>
<hour>6</hour>
<minute>0</minute>
</pubmedpubdate>
</history>
<publicationstatus>ppublish</publicationstatus>
<articleidlist>
<articleid idtype="doi">10.1007/s00213-013-3397-x</articleid>
<articleid idtype="pubmed">24441937</articleid>
</articleidlist>
</pubmeddata>
</pubmedarticle>
<pubmedarticle>
<medlinecitation owner="NLM" status="MEDLINE">
<pmid version="1">24402222</pmid>
<datecreated>
<year>2014</year>
<month>01</month>
<day>09</day>
</datecreated>
<datecompleted>
<year>2014</year>
<month>07</month>
<day>11</day>
</datecompleted>
<article pubmodel="Print-Electronic">
<journal>
<issn issntype="Electronic">1809-452X</issn>
<journalissue citedmedium="Internet">
<volume>35</volume>
<issue>4</issue>
<pubdate>
<medlinedate>2013 Oct-Dec</medlinedate>
</pubdate>
</journalissue>
<title>Revista brasileira de psiquiatria (São Paulo, Brazil : 1999)</title>
<isoabbreviation>Rev Bras Psiquiatr</isoabbreviation>
</journal>
<articletitle>Varenicline: the risks of over-the-counter sales in Brazil.</articletitle>
<pagination>
<medlinepgn>442-3</medlinepgn>
</pagination>
<elocationid eidtype="doi" validyn="Y">10.1590/1516-4446-2013-1107</elocationid>
<elocationid eidtype="pii" validyn="Y">S1516-44462013000400442</elocationid>
<authorlist completeyn="Y">
<author validyn="Y">
<lastname>Zaparoli</lastname>
<forename>Juçara Xavier</forename>
<initials>JX</initials>
<affiliation>Universidade Federal de São Paulo (UNIFESP), Department of Psychobiology, São PauloSP, Brazil.</affiliation>
</author>
<author validyn="Y">
<lastname>Galduróz</lastname>
<forename>José Carlos Fernandes</forename>
<initials>JC</initials>
<affiliation>Universidade Federal de São Paulo (UNIFESP), Department of Psychobiology, São PauloSP, Brazil.</affiliation>
</author>
</authorlist>
<language>eng</language>
<publicationtypelist>
<publicationtype>Letter</publicationtype>
<publicationtype>Research Support, Non-U.S. Gov't</publicationtype>
</publicationtypelist>
<articledate datetype="Electronic">
<year>2013</year>
<month>12</month>
<day>23</day>
</articledate>
</article>
<medlinejournalinfo>
<country>Brazil</country>
<medlineta>Rev Bras Psiquiatr</medlineta>
<nlmuniqueid>100895975</nlmuniqueid>
<issnlinking>1516-4446</issnlinking>
</medlinejournalinfo>
<chemicallist>
<chemical>
<registrynumber>0</registrynumber>
<nameofsubstance>Benzazepines</nameofsubstance>
</chemical>
<chemical>
<registrynumber>0</registrynumber>
<nameofsubstance>Nicotinic Agonists</nameofsubstance>
</chemical>
<chemical>
<registrynumber>0</registrynumber>
<nameofsubstance>Nonprescription Drugs</nameofsubstance>
</chemical>
<chemical>
<registrynumber>0</registrynumber>
<nameofsubstance>Quinoxalines</nameofsubstance>
</chemical>
<chemical>
<registrynumber>W6HS99O8ZO</registrynumber>
<nameofsubstance>varenicline</nameofsubstance>
</chemical>
</chemicallist>
<citationsubset>IM</citationsubset>
<meshheadinglist>
<meshheading>
<descriptorname majortopicyn="N">Benzazepines</descriptorname>
<qualifiername majortopicyn="Y">adverse effects</qualifiername>
</meshheading>
<meshheading>
<descriptorname majortopicyn="N" type="Geographic">Brazil</descriptorname>
</meshheading>
<meshheading>
<descriptorname majortopicyn="N">Humans</descriptorname>
</meshheading>
<meshheading>
<descriptorname majortopicyn="N">Nicotinic Agonists</descriptorname>
<qualifiername majortopicyn="Y">adverse effects</qualifiername>
</meshheading>
<meshheading>
<descriptorname majortopicyn="N">Nonprescription Drugs</descriptorname>
</meshheading>
<meshheading>
<descriptorname majortopicyn="N">Quinoxalines</descriptorname>
<qualifiername majortopicyn="Y">adverse effects</qualifiername>
</meshheading>
<meshheading>
<descriptorname majortopicyn="N">Smoking</descriptorname>
<qualifiername majortopicyn="Y">drug therapy</qualifiername>
</meshheading>
<meshheading>
<descriptorname majortopicyn="Y">Smoking Cessation</descriptorname>
</meshheading>
</meshheadinglist>
</medlinecitation>
<pubmeddata>
<history>
<pubmedpubdate pubstatus="received">
<year>2013</year>
<month>2</month>
<day>18</day>
</pubmedpubdate>
<pubmedpubdate pubstatus="accepted">
<year>2013</year>
<month>4</month>
<day>1</day>
</pubmedpubdate>
<pubmedpubdate pubstatus="aheadofprint">
<year>2013</year>
<month>12</month>
<day>23</day>
</pubmedpubdate>
<pubmedpubdate pubstatus="entrez">
<year>2014</year>
<month>1</month>
<day>10</day>
<hour>6</hour>
<minute>0</minute>
</pubmedpubdate>
<pubmedpubdate pubstatus="pubmed">
<year>2014</year>
<month>1</month>
<day>10</day>
<hour>6</hour>
<minute>0</minute>
</pubmedpubdate>
<pubmedpubdate pubstatus="medline">
<year>2014</year>
<month>7</month>
<day>12</day>
<hour>6</hour>
<minute>0</minute>
</pubmedpubdate>
</history>
<publicationstatus>ppublish</publicationstatus>
<articleidlist>
<articleid idtype="pii">S1516-44462013000400442</articleid>
<articleid idtype="doi">10.1590/1516-4446-2013-1107</articleid>
<articleid idtype="pubmed">24402222</articleid>
</articleidlist>
</pubmeddata>
</pubmedarticle>
<pubmedarticle>
<medlinecitation owner="NLM" status="PubMed-not-MEDLINE">
<pmid version="1">23997753</pmid>
<datecreated>
<year>2013</year>
<month>09</month>
<day>02</day>
</datecreated>
<datecompleted>
<year>2013</year>
<month>09</month>
<day>02</day>
</datecompleted>
<daterevised>
<year>2013</year>
<month>09</month>
<day>04</day>
</daterevised>
<article pubmodel="Print">
<journal>
<issn issntype="Print">1570-159X</issn>
<journalissue citedmedium="Print">
<volume>11</volume>
<issue>2</issue>
<pubdate>
<year>2013</year>
<month>Mar</month>
</pubdate>
</journalissue>
<title>Current neuropharmacology</title>
<isoabbreviation>Curr Neuropharmacol</isoabbreviation>
</journal>
<articletitle>Effects of low doses of polyunsaturated Fatty acids on the attention deficit/hyperactivity disorder of children: a systematic review.</articletitle>
<pagination>
<medlinepgn>186-96</medlinepgn>
</pagination>
<elocationid eidtype="doi" validyn="Y">10.2174/1570159X11311020005</elocationid>
<abstract>
<abstracttext label="UNLABELLED">Since attention deficit/hyperactivity disorder (ADHD) presents high prevalence among children, science has been researching alternative forms of treatment that do not involve medication.</abstracttext>
<abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">To evaluate the effects of polyunsaturated fatty acids (PUFAs) on attention deficit/hyperactivity disorder.</abstracttext>
<abstracttext label="METHODS" nlmcategory="METHODS">We reviewed the articles published between 1980 and 2012 indexed in the databases PubMed, APA psychNET, Scopus and Web of Knowledge.</abstracttext>
<abstracttext label="RESULTS" nlmcategory="RESULTS">Initially 231 articles were selected, out of which 12 met the inclusion criteria. The articles selected reported a modest cognitive and behavioral improvement of the patients after treatment with low doses of PUFAs. Those results might be associated with the evaluation methodology, the doses of PUFAs administered or the duration of treatment.</abstracttext>
</abstract>
<authorlist completeyn="Y">
<author validyn="Y">
<lastname>Grassmann</lastname>
<forename>Viviane</forename>
<initials>V</initials>
<affiliation>Department of Psychobiology (Departamento de Psicobiologia) - Universidade Federal de São Paulo - Brazil.</affiliation>
</author>
<author validyn="Y">
<lastname>Santos-Galduróz</lastname>
<forename>Ruth Ferreira</forename>
<initials>RF</initials>
</author>
<author validyn=""></author></authorlist></article></medlinecitation></pubmedarticle></pubmedarticleset></body></html>]
In [ ]:
Content source: jasonost/clinicaltrials
Similar notebooks: